loading
Promis Neurosciences Inc stock is traded at $0.49, with a volume of 55,602. It is down -2.00% in the last 24 hours and down -23.44% over the past month. ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$0.50
Open:
$0.48
24h Volume:
55,602
Relative Volume:
1.39
Market Cap:
$16.02M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-2.4549
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
-8.26%
1M Performance:
-23.44%
6M Performance:
-45.56%
1Y Performance:
-70.48%
1-Day Range:
Value
$0.4797
$0.56
1-Week Range:
Value
$0.47
$0.586
52-Week Range:
Value
$0.47
$2.37

Promis Neurosciences Inc Stock (PMN) Company Profile

Name
Name
Promis Neurosciences Inc
Name
Phone
416-847-6898
Name
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
PMN's Discussions on Twitter

Compare PMN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PMN
Promis Neurosciences Inc
0.49 17.46M 0 -563.30K -22.23M -0.1996
Biotechnology icon
ONC
Beone Medicines Ltd Adr
251.72 25.78B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.48 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3401 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.81 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
487.86 65.13B 14.09B 4.50B 2.96B 39.28

Promis Neurosciences Inc Stock (PMN) Latest News

pulisher
May 18, 2025

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying - MSN

May 18, 2025
pulisher
May 14, 2025

ProMIS Neurosciences Reports Q1 2025 Progress and Financials - TipRanks

May 14, 2025
pulisher
May 13, 2025

ProMIS Neurosciences (NASDAQ:PMN) Now Covered by Maxim Group - Defense World

May 13, 2025
pulisher
May 13, 2025

ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 12, 2025

ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences (PMN): Maxim Group Initiates Coverage with Buy Rating | PMN Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Maxim Group Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation - Nasdaq

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Resu - GuruFocus

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences (PMN) Advances Alzheimer's Clinical Program - GuruFocus

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Results - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Results | PMN Stock News - GuruFocus

May 12, 2025
pulisher
Apr 26, 2025

Multiple System Atrophy Treatment Algorithm, Clinical Trials - openPR.com

Apr 26, 2025
pulisher
Apr 17, 2025

Parkinson’s vaccine selectively targets pathogenic αSyn - BioWorld MedTech

Apr 17, 2025
pulisher
Apr 04, 2025

ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India

Apr 04, 2025
pulisher
Apr 04, 2025

Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN

Apr 04, 2025
pulisher
Apr 02, 2025

ProMIS Neurosciences’ (PMN) Buy Rating Reaffirmed at Guggenheim - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

ProMIS Neurosciences Reports 2024 Financial Turnaround - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

PROMIS NEUROSCIENCES Earnings Results: $PMN Reports Quarterly Earnings - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Inc. (PMN) reports earnings - Quartz

Mar 31, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Form 424B5 ProMIS Neurosciences - StreetInsider

Mar 31, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 28, 2025

ProMIS Neurosciences Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView

Mar 28, 2025
pulisher
Mar 25, 2025

ProMIS to present neurodegenerative disease research By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

New Diagnostics And Treatments Transform Neurodegenerative Disease Care - Evrim Ağacı

Mar 24, 2025
pulisher
Mar 24, 2025

ProMIS to present neurodegenerative disease research - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference - Yahoo Finance

Mar 24, 2025
pulisher
Mar 23, 2025

ProMIS Neurosciences (PMN) Expected to Announce Quarterly Earnings on Monday - Defense World

Mar 23, 2025
pulisher
Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth - openPR

Mar 20, 2025
pulisher
Mar 13, 2025

ProMIS to present vaccine data at neurology meeting By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS to present vaccine data at neurology meeting - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS Neurosciences to Present Preclinical Data on Computational Vaccine Development for Neurodegenerative Diseases at AAN Annual Meeting - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform - GlobeNewswire

Mar 13, 2025
pulisher
Mar 12, 2025

PROMIS NEUROSCIENCES Earnings Preview: Recent $PMN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 12, 2025
pulisher
Mar 11, 2025

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 01, 2025

ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World

Mar 01, 2025
pulisher
Feb 25, 2025

ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

ProMIS Neurosciences begins Alzheimer’s trial dosing By Investing.com - Investing.com South Africa

Feb 25, 2025

Promis Neurosciences Inc Stock (PMN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price down icon 0.60%
Cap:     |  Volume (24h):